These results indicate that DSD drugs may act on AKT1, EGFR, TP53, and TNF through formononetin, isorhamnetin, β-Sitosterol, and kaempferol, thereby playing a role in treating MI. Here, AKT1 is linked to disorder of sexual differentiation.